Comprehensive analysis supports routine use of metabolic drug for people with all levels of kidney function
2025-11-08
(Press-News.org) In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two companion papers in JAMA, the findings are based on data from over 70,000 participants across 10 major randomised controlled trials. The meta-analyses were conducted by the SGLT2 Inhibitor Meta-analysis Cardio-Renal Trialists’ Consortium (SMART-C), led by The George Institute for Global Health.
SGLT2 inhibitors, originally developed to treat type 2 diabetes, have since demonstrated substantial protection against heart failure and chronic kidney disease (CKD).3 However, questions remained about their effectiveness in people with advanced CKD or those with low levels of albuminuria (protein in the urine – a sign of early kidney disease), and whether benefits extended equally to those without diabetes.
In the first analysis, researchers found that SGLT2 inhibitors reduced the risk of CKD progression by 38% versus placebo and were similar across patients regardless of their kidney function (measured by estimated glomerular filtration rate or eGFR). SGLT2 inhibitors slowed the annual rate of eGFR decline by 51% versus placebo, with benefits across all levels of kidney function and rates of albuminuria.
Importantly, these effects were observed even in people with stage 4 CKD (eGFR <30 mL/min/1.73m²) and those with minimal or no albuminuria (urine albumin-creatinine ratio, uACR ≤30 mg/g) – groups for whom SGLT2 inhibitor treatment recommendations have not been clear.
The second analysis focused on the benefits and risks of SGLT2 inhibitors by diabetes status and albuminuria level. It found that substantial benefits were also for all patients, particularly in reducing hospitalisations. Heart failure hospitalisations were reduced by nearly a third in patients with diabetes and a quarter in those without. The risk of serious adverse events was low and considerably outweighed by the health and mortality benefits.
Associate Professor Brendon Neuen, Renal and Metabolic Program Lead at The George Institute and lead author of one of the studies, said the findings provide the strongest evidence yet to support widespread use of SGLT2 inhibitors in people with CKD.
“SGLT2 inhibitors are a powerful tool to reduce the burden of kidney failure, hospitalisation and premature death in patients with diabetes, CKD, or heart failure. These findings indicate that many more individuals than are currently being treated stand to benefit, highlighting a major opportunity to improve population health.” he said.
“Our findings support simplifying treatment guidelines to encourage broader use of these medicines.”
CKD affects around one in ten people globally – approximately 850 million individuals – and is a leading cause of death and disability.4 The burden of CKD is highest in low- and middle-income countries where access to SGLT2 inhibitors remains low.
“As these medicines become more affordable and widely available in generic form over the next few years, we have a once-in-a-generation opportunity to transform care for millions of people living with or at risk of developing kidney disease around the world.”
SMART-C is co-chaired by A/Prof Brendon Neuen and Professor Hiddo Heerspink of The George Institute for Global Health.
-ends-
References
Neuen BL, et al. SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: A collaborative meta-analysis. JAMA. 2025. https://doi.org/10.1001/jama.2025.20834
Staplin N, et al. Absolute effects of sodium glucose co-transporter-2 inhibitors by diabetes status and level of albuminuria: A SMART-C meta-analysis. JAMA. 2025. https://doi.org/10.1001/jama.2025.20835
The Nuffield Department of Population Health and the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022. https://doi.org/10.1016/S0140-6736(22)02074-8
Kovesdy CP, et al. Epidemiology of chronic kidney disease: an update 2022. Kidney Iny Suppl. 2022. https://doi.org/10.1016/j.kisu.2021.11.003 END
ELSE PRESS RELEASES FROM THIS DATE:
2025-11-08
Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at Amsterdam UMC investigated whether this dysregulation can be prevented by starting HIV medication immediately after infection – i.e. within a few days. They saw that six months after this early treatment, the immune system did indeed work as in people without HIV. But in the longer term, the immune system was disrupted again. This is shown by research by Amsterdam UMC, published in the journal EBioMedicine.
Early treatment protects immune systems only temporarily
For this study, the scientists examined ...
2025-11-08
Record numbers of men and women globally are now estimated to have reduced kidney function, a new study shows. Figures rose from 378 million people with the disease in 1990 to 788 million in 2023 as the world population grew and aged, making it for the first time a top 10 cause of death worldwide.
Led by researchers at NYU Langone Health, the University of Glasgow, and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, the analysis explored the rise of the illness, in which the kidneys gradually lose their ability to filter waste and excess fluid from the blood. Mild cases may have no symptoms while the most severe stages ...
2025-11-08
In 2023, chronic kidney disease (CKD) was the 9th-leading cause of death worldwide, responsible for nearly 1.5 million deaths.
Unlike most other leading causes of death, CKD mortality rates continue to rise, signaling a growing global health crisis.
In 2023, CKD ranked as the 12th-leading cause of disability worldwide and the 7th-leading driver of cardiovascular deaths. Kidney dysfunction alone accounted for almost 12% of all global cardiovascular deaths.
Diabetes, obesity, and high blood pressure remain the top drivers of CKD, alongside dietary risks and environmental factors.
SEATTLE, Wash. – Nov. 7, ...
2025-11-08
About The Study: The results of this study suggest that community health workers played a vital role in improving patient engagement, emotional wellbeing, and self-efficacy, suggesting their integration into dialysis care teams may enhance holistic, patient-centered care.
Corresponding Author: To contact the corresponding author, Lilia Cervantes, MD, email Lilia.Cervantes@cuanschutz.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2025.48506)
Editor’s ...
2025-11-08
About The Study: In this randomized clinical trial, a culturally tailored community health worker intervention modestly lowered interdialytic weight gain and improved dialysis adherence and patient activation among Hispanic and Latino patients with hemodialysis-dependent kidney failure.
Corresponding Author: To contact the corresponding author, Lilia Cervantes, MD, MSc, email lilia.cervantes@cuanschutz.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2025.5305)
Editor’s Note: Please see the article for additional information, including other authors, author ...
2025-11-07
As China’s most important grain-producing region, Northeast China plays a vital role in safeguarding national food security. Yet this agricultural powerhouse faces a growing dilemma: how to maintain high crop yields while protecting the fragile ecosystems that sustain long-term productivity. A new study published in Agricultural Ecology and Environment identifies the key conflicts between agricultural expansion and ecological protection in the region and proposes integrated strategies to achieve a more sustainable balance.
Over the past four decades, Northeast China’s farmlands ...
2025-11-07
SAN ANTONIO, Nov. 7, 2025 – Traumatic brain injury, or TBI, affects millions of Americans each year, often resulting in long-term health challenges. New national recommendations are now paving the way for more effective short- and long-term care for patients with TBI.
Monica Verduzco-Gutierrez, MD, a physiatrist with UT Health San Antonio, the academic health center of The University of Texas at San Antonio, and professor and chair of the Department of Physical Medicine and Rehabilitation at UT San Antonio’s Long School of Medicine, served on the National Academies of Sciences, ...
2025-11-07
As the planet warms and rainfall patterns shift, new research suggests that the world’s largest grassland region may become a growing source of nitrous oxide, a greenhouse gas nearly 300 times more potent than carbon dioxide.
A team of scientists led by Dr. Shuping Qin from the Chinese Academy of Sciences examined how soil and climate conditions control the process of denitrification, a key microbial pathway that converts nitrogen compounds in soil into gases including nitrous oxide (N₂O) and nitrogen gas (N₂). Their study, recently published in Environmental and Biogeochemical Processes, is the first to map how denitrification responds ...
2025-11-07
Houston, TX (November 7, 2025) — New research reveals that contrary toconventional belief, primary glomerular diseases are not necessarily benign for children and young adults. In fact, some subsets of children and young adults may experience faster kidney function decline than older patients. The findings will be presented at ASN Kidney Week 2025 November 5–9.
Direct comparisons of outcomes between adult and pediatric patients with primary glomerular diseases are rare—including minimal change disease (MCD), focalsegmental ...
2025-11-07
Houston, TX (November 7, 2025) — Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and kidney- protective effects. In the kidney, SGLT2 reabsorbs approximately 97% offiltered glucose in the S1 and S2 segments of the proximal tubule, while SGLT1reabsorbs the remainder in the S3 segment. In research conducted in rats, investigators found that dual inhibition of SGLT1 and SGLT2 more effectively reduces salt-sensitive hypertension and kidney injury than SGLT2 inhibition alone. The findings will be presented ...
LAST 30 PRESS RELEASES:
[Press-News.org] Comprehensive analysis supports routine use of metabolic drug for people with all levels of kidney function
